scholarly journals The conserved threonine-rich region of the HCF-1PRO repeat activates promiscuous OGT:UDP-GlcNAc glycosylation and proteolysis activities

2018 ◽  
Vol 293 (46) ◽  
pp. 17754-17768 ◽  
Author(s):  
Vaibhav Kapuria ◽  
Ute F. Röhrig ◽  
Patrice Waridel ◽  
Fabienne Lammers ◽  
Vladimir S. Borodkin ◽  
...  

O-Linked GlcNAc transferase (OGT) possesses dual glycosyltransferase–protease activities. OGT thereby stably glycosylates serines and threonines of numerous proteins and, via a transient glutamate glycosylation, cleaves a single known substrate—the so-called HCF-1PRO repeat of the transcriptional co-regulator host-cell factor 1 (HCF-1). Here, we probed the relationship between these distinct glycosylation and proteolytic activities. For proteolysis, the HCF-1PRO repeat possesses an important extended threonine-rich region that is tightly bound by the OGT tetratricopeptide-repeat (TPR) region. We report that linkage of this HCF-1PRO-repeat, threonine-rich region to heterologous substrate sequences also potentiates robust serine glycosylation with the otherwise poor Rp-αS-UDP-GlcNAc diastereomer phosphorothioate and UDP-5S-GlcNAc OGT co-substrates. Furthermore, it potentiated proteolysis of a non-HCF-1PRO-repeat cleavage sequence, provided it contained an appropriately positioned glutamate residue. Using serine- or glutamate-containing HCF-1PRO-repeat sequences, we show that proposed OGT-based or UDP-GlcNAc–based serine-acceptor residue activation mechanisms can be circumvented independently, but not when disrupted together. In contrast, disruption of both proposed activation mechanisms even in combination did not inhibit OGT-mediated proteolysis. These results reveal a multiplicity of OGT glycosylation strategies, some leading to proteolysis, which could be targets of alternative molecular regulatory strategies.

2011 ◽  
Vol 108 (7) ◽  
pp. 2747-2752 ◽  
Author(s):  
S. Daou ◽  
N. Mashtalir ◽  
I. Hammond-Martel ◽  
H. Pak ◽  
H. Yu ◽  
...  

1951 ◽  
Vol 29 (3) ◽  
pp. 144-148
Author(s):  
R. C. French ◽  
S. M. Lesley ◽  
A. F. Graham ◽  
C. E. van Rooyen

Infection of E. coli with T2r, T4r+, T4r, T5, T6r+, or T6r phages induces the formation of a mechanism which extensively degrades P32 labelled T2r+ phage adsorbed to the cell shortly afterwards, about 50% of the P32 being converted to a form soluble in 5% trichloroacetic acid. Each of the above viruses is as effi cient in this respect as a preliminary infection with T2r+ phage itself. Previous infection of the cells with Tl, T3, or T7 phages does not stimulate this mechanism to break down labelled T2r+ virus. When Tl, T3, or T7 phage, then T2r+ phage, and finally P32 labelled T2r+ phage were added to cells, with an interval of several minutes between each addition, the results indicated that adsorption of T2r+ to the cell was not sufficient per se to stimulate the breakdown of labelled phage. Apparently actual infection of the cell by T2r+ virus was required before the breakdown mechanism was induced.


Transcription ◽  
2012 ◽  
Vol 3 (4) ◽  
pp. 187-192 ◽  
Author(s):  
Zaffer Ullah Zargar ◽  
Shweta Tyagi

2020 ◽  
Vol 78 (2) ◽  
Author(s):  
Elinor Hortle ◽  
Stefan H Oehlers

ABSTRACT Mycobacteria have co-evolved with their hosts resulting in pathogens adept at intracellular survival. Pathogenic mycobacteria actively manipulate infected macrophages to drive granuloma formation while subverting host cell processes to create a permissive niche. Granuloma residency confers phenotypic antimicrobial resistance by physically excluding or neutralising antibiotics. Host-directed therapies (HDTs) combat infection by restoring protective immunity and reducing immunopathology independent of pathogen antimicrobial resistance status. This review covers innovative research that has discovered ‘secondary’ symptoms of infection in the granuloma stroma are actually primary drivers of infection and that relieving these stromal pathologies with HDTs benefits the host. Advances in our understanding of the relationship between tuberculosis and the host vasculature, haemostatic system and extracellular matrix reorganisation are discussed. Preclinical and clinical use of HDTs against these stromal targets are summarised.


2019 ◽  
Author(s):  
Tessa M. Popay ◽  
Lance R. Thomas ◽  
Jing Wang ◽  
Qi Liu ◽  
William P. Tansey

Sign in / Sign up

Export Citation Format

Share Document